# US 2012/0252855 A1 · Methods For Treating Degenerative Diseases/Injuries

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252855 A1
- Document ID: US20120252855A1
- Status: Published application
- Kind: A1
- Application number: 13/409,324
- Filed: 2012-03-01
- Published: 2012-10-04
- Earliest claimed: 2003-04-29
- Inventors: Connie ERICKSON-MILLER; Julian JENKINS
- Web page: https://patentgrep.com/patent/US20120252855A1

## CPC

- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

## Claims

### Claim 1

A method of treating cardiovascular disease in a human in need thereof which comprises the in vivo administration of a therapeutically effective amount of a compound selected from
3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid,
or a pharmaceutically acceptable salt thereof, and
3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl,
or a pharmaceutically acceptable salt thereof;
to such human.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the compound is 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A method according to claim 1 wherein the compound is 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid bis-(monoethanolamine).

### Claim 4 (depends on 3)

A method according to claim 3 wherein the cardiovascular disease is myocardial infarction.

### Claim 5 (depends on 3)

A method according to claim 3 wherein the human is in need of treatment for repair of cardiovascular tissue.

### Claim 6 (depends on 3)

A method according to claim 3 wherein the human is in need of tissue reparation for cardiovascular disorders.

### Claim 7 (depends on 6)

A method according to claim 6 wherein the cardiovascular disorder occurred during cardiac bypass surgery.

### Claim 8 (depends on 6)

A method according to claim 6 wherein the cardiovascular disorder occurred during heart surgery.

### Claim 9 (depends on 8)

A method according to claim 8 wherein the heart surgery was heart transplant surgery.

### Claim 10 (depends on 8)

A method according to claim 8 wherein the compound is administered prior to heart surgery.

### Claim 11 (depends on 3)

A method according to claim 3 wherein the compound is administered orally.

### Claim 12 (depends on 3)

A method according to claim 3 wherein the compound is administered parenterally.

### Claim 13 (depends on 11)

A method according to claim 11 wherein the compound is administered in tablet form.

### Claim 14 (depends on 3)

A method according to claim 3 wherein the cardiovascular disease is due to viral, fungal, microbial or parasitic infection.

### Claim 15 (depends on 3)

A method according to claim 3 wherein the cardiovascular disease is due to surgical procedures.

### Claim 16 (depends on 3)

A method according to claim 3 wherein the cardiovascular disease is due to treatment with antiviral or antibiotic agents.

### Claim 17 (depends on 13)

A method according to claim 13 wherein the tablet contains an amount from 0.05 to 3500 mg of active compound.

### Claim 18 (depends on 13)

A method according to claim 13 wherein the tablet contains an amount from 0.1 to 3000 mg of active compound.

### Claim 19 (depends on 13)

A method according to claim 13 wherein the tablet contains 20 mg of active compound.

### Claim 20 (depends on 3)

A method according to claim 3 wherein the cardiovascular disease is due to treatment with a pharmaceutically active agent.

### Claim 21 (depends on 3)

A method according to claim 3 wherein the cardiovascular disease is due to treatment with an anti-neoplastic agent.

### Claim 22 (depends on 21)

A method according to claim 21 wherein the cardiovascular disease is due to treatment with a chemotherapeutic agent.

### Claim 23 (depends on 21)

A method according to claim 21 wherein the cardiovascular disease is due to treatment with a tyrosine kinase inhibiting compound.

### Claim 24 (depends on 21)

A method according to claim 21 wherein the cardiovascular disease is due to treatment at least one compound selected from: Doxorubicin, herceptin, Gleevac, Sprycel, Tasigna, Sutent, Nexavar, Avastin, Tykerb, Iressa, Tarceva, Erbitux and Panitumumab.

### Claim 25 (depends on 3)

A method according to claim 3 wherein the cardiovascular disease is due to treatment with radiation therapy.

### Claim 26 (depends on 20)

A method according to claim 20 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.

### Claim 27 (depends on 20)

A method according to claim 20 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.

### Claim 28 (depends on 20)

A method according to claim 20 wherein the compound is administered in a tablet that contains 20 mg of active compound.

### Claim 29 (depends on 21)

A method according to claim 21 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.

### Claim 30 (depends on 21)

A method according to claim 21 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.

### Claim 31 (depends on 21)

A method according to claim 21 wherein the compound is administered in a tablet that contains 20 mg of active compound.

### Claim 32 (depends on 4)

A method according to claim 4 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.

### Claim 33 (depends on 4)

A method according to claim 4 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.

### Claim 34 (depends on 4)

A method according to claim 4 wherein the compound is administered in a tablet that contains 20 mg of active compound.

### Claim 35 (depends on 3)

A method according to claim 3 wherein the compound is administered prior to heart surgery.

### Claim 36 (depends on 3)

A method according to claim 3 wherein the compound is administered prior to treatment with a pharmaceutically active agent.

### Claim 37 (depends on 3)

A method according to claim 3 wherein the compound is administered prior to treatment with an anti-neoplastic agent.

### Claim 38 (depends on 3)

A method according to claim 3 wherein the compound is administered prior to treatment with a chemotherapeutic agent.

### Claim 39 (depends on 3)

A method according to claim 3 wherein the compound is administered prior to treatment with a tyrosine kinase inhibiting compound.
